Masey Ross is an Oncology physician affiliated with Virginia Commonwealth University. OpenAlex indexes 18 publications with 296 citations (h-index 4).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GenentechProgram year20252 paymentsResearch$52,408openpaymentsdata.cms.gov ↗
- AstraZenecaProgram year20251 paymentResearch$33,781openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
73.8%Aromatase Inhibitor65.1%Anastrozole86%Letrozole14%Part D<11 patientsEstrogen Agonist/Antagonist8.7%Tamoxifen Citrate100%Part D<11 patientsMetabolism & gastrointestinal
9.4%Serotonin-3 Receptor Antagonist9.4%Ondansetron Hcl100%Part D<11 patientsGenitourinary & hormones
8.7%Estrogen Agonist/Antagonist8.7%Raloxifene Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE
JNCI Journal of the National Cancer Institute
2026 - 26-A-13210-ACC ELEVATED CALCIFIED CORONARY PLAQUE IN PREMENOPAUSAL WOMEN WITH TRIPLE NEGATIVE BREAST CANCER TREATED WITH IMMUNE CHECKPOINT BLOCKADE
Journal of the American College of Cardiology
2026
Similar KOLs
Other experts from the same institution or the same specialty.
Jasmohan Bajaj, MD
Virginia Commonwealth University
Patrick Ching, MD, MPH
Virginia Commonwealth University
Bruce Rubin, MD
Virginia Commonwealth University
Nicole Karjane, MD
Virginia Commonwealth University
Carl June, MD
University of Pennsylvania
Stuart Orkin, MD
Harvard Medical School
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”